oxybutynin has been researched along with Deep Vein Thrombosis in 7 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Incidence rate of venous thrombosis in users of transdermal, vaginal, intrauterine, or subcutaneous hormonal contraception, relative risk of venous thrombosis compared with non-users, and rate ratios of venous thrombosis in current users of non-oral products compared with the standard reference oral contraceptive with levonorgestrel and 30-40 µg oestrogen." | 3.78 | Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. ( Lidegaard, O; Løkkegaard, E; Nielsen, LH; Skovlund, CW, 2012) |
| "The annual risk of venous thrombosis has been estimated at 5 to 10 cases per 100 000 women aged 15 to 44 years who are not using hormonal contraception." | 2.49 | Thrombotic risk of contraceptive transdermal patches and the contraceptive vaginal ring. ( , 2013) |
| "However, the risk of venous thrombosis (VT) associated with OC use in women over 50 years old has never been assessed and the two preparations have not been directly compared." | 1.39 | The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. ( Cannegieter, SC; Helmerhorst, FM; Lijfering, WM; Roach, RE; Rosendaal, FR; van Hylckama Vlieg, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, W | 1 |
| Drummond, A | 1 |
| Kelly, M | 1 |
| Mohammed, K | 1 |
| Abu Dabrh, AM | 1 |
| Benkhadra, K | 1 |
| Al Nofal, A | 1 |
| Carranza Leon, BG | 1 |
| Prokop, LJ | 1 |
| Montori, VM | 1 |
| Faubion, SS | 1 |
| Murad, MH | 1 |
| Raps, M | 1 |
| Helmerhorst, F | 1 |
| Fleischer, K | 1 |
| Thomassen, S | 1 |
| Rosendaal, F | 1 |
| Rosing, J | 1 |
| Ballieux, B | 1 |
| VAN Vliet, H | 1 |
| Lidegaard, O | 1 |
| Nielsen, LH | 1 |
| Skovlund, CW | 1 |
| Løkkegaard, E | 1 |
| Połać, I | 1 |
| Borowiecka, M | 1 |
| Wilamowska, A | 1 |
| Nowak, P | 1 |
| Roach, RE | 1 |
| Lijfering, WM | 1 |
| Helmerhorst, FM | 1 |
| Cannegieter, SC | 1 |
| Rosendaal, FR | 1 |
| van Hylckama Vlieg, A | 1 |
2 reviews available for oxybutynin and Deep Vein Thrombosis
| Article | Year |
|---|---|
Thrombotic risk of contraceptive transdermal patches and the contraceptive vaginal ring.
Topics: Administration, Intravaginal; Contraceptive Agents, Female; Female; Humans; Risk; Transdermal Patch; | 2013 |
Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis.
Topics: Administration, Oral; Estrogen Replacement Therapy; Evidence-Based Medicine; Female; Humans; Menopau | 2015 |
1 trial available for oxybutynin and Deep Vein Thrombosis
| Article | Year |
|---|---|
Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
Topics: Administration, Oral; Blood Coagulation; Cardiovascular Diseases; Drug Combinations; Dydrogesterone; | 2013 |
4 other studies available for oxybutynin and Deep Vein Thrombosis
| Article | Year |
|---|---|
Deep vein thrombosis in a transgender woman.
Topics: Adult; Ankle Injuries; Deprescriptions; Estradiol; Estrogen Replacement Therapy; Estrogens; Factor X | 2017 |
Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives.
Topics: Activated Protein C Resistance; Administration, Cutaneous; Adolescent; Adult; Biomarkers; Blood Coag | 2012 |
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10.
Topics: Adolescent; Adult; Anticoagulants; Contraceptive Agents, Female; Contraceptive Devices, Female; Cont | 2012 |
The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy.
Topics: Administration, Cutaneous; Age Factors; Aged; Case-Control Studies; Contraceptives, Oral, Hormonal; | 2013 |